Abstract
Aim:
To investigate the preventive and protective effects of bendazac lysine (BDL) on experimental early diabetic nephropathy (DN) rats.
Methods:
After an early DN model was induced by streptozotocin, rats were administered BDL at doses of 100, 200, and 400 mg/kg for 8 weeks. Blood glucose, microalbuminuria, kidney index, total antioxidative capacity, laminin, advanced glycation end products (AGE), aldose reductase (AR) activity, and the relative quantity of transforming growth factor β1 (TGF-β1) mRNA were measured by different methods. The ultrastructural morphology was observed by transmission electron microscope.
Results:
The physical behaviors of early DN rats were hypopraxia, cachexia, and polyuria, while those treated with high doses of BDL were vibrant and vigorous. For BDL-treated DN rats, when compared with vehicle-treated DN rats, the blood glucose level and the intensity of oxidative stress were ameliorated. Also, the micro albuminuria level, AGE either in serum or in renal, and AR activity were significantly reduced. Furthermore, the expression of TGF-β1 mRNA in the kidney cortex was declined and the thickness of glomerular base membrane was decreased significantly. The ultrastructure of glomerulus and mesangial matrix of BDL-treated DN rats were ameliorated.
Conclusion:
BDL has protective effects on several pharmacological targets in the progress of DN and is a potential drug for the prevention of early DN.
Similar content being viewed by others
Article PDF
References
Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER . Glucose-induced oxidative stress in mesangial cells. Kidney Int 2002; 61: 599–608.
Wautier JL, Guillausseau PJ . Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535–42.
Cooper ME . Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–72.
Sharma K, McGowan Tracy A . TGF-β in diabetic kidney: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115–23.
Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67–73.
Balfour JA, Clissold SP . Bendazac lysine: a review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990; 39: 575–96.
Inliano G, Menzion M, Apponi-Battini G, Costagliola C . Inhibition of rat lens aldose reductase by bandazac-L-lysine salt. Enzyme 1989; 42: 235–7.
Schmut O, Hofmann H . Studies on the activity of bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radials. Wien Klin Wochenschr 1985; 97: 819–22.
Marques C, Ramalho JS, Pereira P, Mota MC . Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol 1995; 90: 395–404.
Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A . A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12.
Das B, Srivastava SK . Purification and properties of aldose reductase and aldehyde reductase II from human erythrocyte. Arch Biochem Biophy 1985; 238: 670–9.
Kaneto H, Morrissey J, Klahr S . Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313–21.
Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Lefebvre PJ . Metabolic control may influence the increased superoxide generation in diabetic serum. Diabetic Med 1991; 8: 540–2.
Schmut, Fellinger C, Hofmann H . Bendazac lysine: a protective substance against oxygen-free radicals. In: D'Ermo F . Recent developments in the pharmacological treatment of cataract. Amsterdam: Kugler Publications; 1987. p 69–72.
Schleicher ED, Wagner E, Nerlich AG . Increased accumulation of the glycoxidation product Nɛ-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457–68.
Ihm SH, Yoo HJ, Park SW, Ihm J . Effect of aminiguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999; 48: 1141–5.
Min C, Kang E, Yu SK, Shinn SH, Kim YS . Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diab Res Clin Pract 1999; 46: 197–202.
Lewis BS, Harding JJ . The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis. Exp Eye Res 1988; 47: 217–25.
Lewis BS, Rixon KC, Harding JJ . Bendazac prevents cyanate binging to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract. Exp Eye Res 1986; 43: 973–9.
Jandeleit-Dahm K, Cao ZM, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME . Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999; 56 ( Suppl 71): S31–6.
Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, et al. F-2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 2000; 58: 1963–72.
Yin XX, Zhang YD, Wu HW, Zhu X, Zheng XG, Jiang SJ, et al. Protective effects of Astragalus Sapoonin I on early stage of diabetic nephropathy in rats. J Pharmacol Sci 2004; 95: 256–66.
Greene DA, Lattimer SA, Sima AAF . Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complicatins. N Engl J Med 1987; 316: 599–606.
Ishii H, Tada H, Isogai S . An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured human mesangial cells. Diabetologia 1998; 41: 362–4.
Suzuki K, Kawamura T, Sakakibara F, Sasaki H, Sano T, Sakamoto N, et al. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myoinositol metabolism in human neutrophils. Diabet Med 1999; 16: 67–73.
Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539–44.
Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, et al. Aldose reductase inhibition ameliorates papillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 2001; 24: 1093–8.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yin, Xx., Zhang, Yd., Shen, Jp. et al. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. Acta Pharmacol Sin 26, 721–728 (2005). https://doi.org/10.1111/j.1745-7254.2005.00111.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00111.x
Keywords
This article is cited by
-
The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation
Acta Pharmacologica Sinica (2019)
-
Glyoxylate induces renal tubular cell injury and microstructural changes in experimental mouse
Urological Research (2008)